Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Additional Locations, Utah Clinical Trials

A listing of Additional Locations, Utah clinical trials actively recruiting patient volunteers.

RESULTS

Found (5) clinical trials

A Study of DSP-0337 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile

The study is comprised of two parts: an initial dose escalation phase utilizing a 3 + 3 design to determine maximum tolerated dose followed by a dose expansion cohort in approximately 30 additional subjects. Study participants will initially receive DSP-0337 orally for 28 days (one cycle of treatment). If clinical ...

Phase

4.39 miles

Learn More »

Hyperbaric Oxygen Neutrophil-oxidative Burst and Cytokines

The investigators are interested in studying the influence of hyperbaric oxygen on neutrophils (a kind of white blood cell) and cytokines (cell proteins). Hyperbaric oxygen can enhance the way the immune system works, but the investigators don't fully know how that happens. the investigators are doing this study to learn ...

Phase

5.51 miles

Learn More »

A Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of TAK-994 in Healthy Participants

The drug being tested in this study is called TAK-994. TAK-994 is being tested to find a safe and well-tolerated dose in healthy participants (non-Japanese and Japanese) and healthy elderly participants. The study will enroll up to approximately 152 healthy participants. The study consists of 5 parts and up to ...

Phase

5.51 miles

Learn More »

Evaluation of the Safety Tolerability and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease

This is a Phase 1b, open-label, dose-escalation, signal-finding, multi-center study. The study will evaluate the safety, tolerability, pharmacokinetics and short-term efficacy of MDGN-002 in adults with moderate to severe, active Crohn's disease who have previously failed anti-tumor necrosis factor alpha (anti-TNF) treatment.

Phase

6.93 miles

Learn More »

Safety and Efficacy Study of RP4010 in Patients With Relapsed or Refractory Lymphomas

Safety: Treatment-Emergent Adverse Events (AE); Treatment related AE, Serious Adverse Events (SAE) and Clinical significant AE; Dose Limiting Toxicities (DLT). Pharmacokinetics (PK): Peak Plasma Concentration (Cmax), Area under the plasma concentration versus time curve (AUC), Time of Maximum Concentration Observed (Tmax). Efficacy: Overall Response Rate (ORR), Progression Free Survival (PFS); ...

Phase

8.03 miles

Learn More »